Photocure revenue remains stable in third quarter of 2026
Photocure ASA reported third-quarter revenues of NOK 134.2 million, showing minimal change compared to the same period in 2025.
Oslo-based life sciences company Photocure ASA recorded revenues of NOK 134.2 million for Hexvix/Cysview during the third quarter of 2026. The performance remains nearly identical to the NOK 134.1 million reported in the third quarter of 2025.
Adjusted EBITDA for the period reached NOK 18.5 million, a slight decrease from the NOK 18.9 million posted in the prior year. The figures highlight a consistent demand for the company’s bladder cancer detection technology.
Photocure continues to focus on its core diagnostics business. The company has updated its outlook for the remainder of 2026 as it navigates current market conditions.